{
"NDC": [
{
"NDCCode": "83014-0002-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0002-1) ",
"NDC11Code": "83014-0002-01",
"ProductNDC": "83014-0002",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus Adrenal",
"NonProprietaryName": "Glycyrrhiza Glabra, Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Aralia Quinquefolia, Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Glandula Suprarenalis (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Adrenocorticotrophin",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20230321",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "GLYCYRRHIZA GLABRA; FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; AMERICAN GINSENG; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS ADRENAL GLAND; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CORTICOTROPIN",
"StrengthNumber": "1; 2; 3; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 15",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Adrenocorticotropic Hormone [CS], Adrenocorticotropic Hormone [EPC], Allergens [CS], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Dietary Proteins [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-03-10",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20230321",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant, to control empty feeling in stomach otherwise relieved by eating, helps with metabolic tendencies to gain weight, cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides adrenal support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0001-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0001-1) ",
"NDC11Code": "83014-0001-01",
"ProductNDC": "83014-0001",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus Female Balance",
"NonProprietaryName": "Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Caulophyllum Thalictroides, Cimicifuga Racemosa, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Rubus Idaeus, Thyroidinum (bovine), Pituitarum Posterium Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Hepar Sulphuris Calcareum, Oxytocin, Progesterone",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20230321",
"EndMarketingDate": "20290214",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; CAULOPHYLLUM THALICTROIDES ROOT; BLACK COHOSH; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; RUBUS IDAEUS LEAF; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CALCIUM SULFIDE; OXYTOCIN; PROGESTERONE",
"StrengthNumber": "2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 12; 30; 30",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Increased Uterine Smooth Muscle Contraction or Tone [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Oxytocic [EPC], Oxytocin [CS], Plant Proteins [CS], Progesterone [CS], Progesterone [EPC], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2024-05-15",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230321",
"EndMarketingDatePackage": "20290214",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides female hormonogenic balance support. †. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0003-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0003-1) ",
"NDC11Code": "83014-0003-01",
"ProductNDC": "83014-0003",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus Male Balance",
"NonProprietaryName": "Agnus Castus, Foeniculum Vulgare, Ammonium Bromatum, Caladium Seguinum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Selenium Metallicum, Adrenalinum, Phosphorus, Orchitinum (bovine), Onosmodium Virginianum",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20230310",
"EndMarketingDate": "20280614",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "CHASTE TREE FRUIT; FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; DIEFFENBACHIA SEGUINE WHOLE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; SELENIUM; EPINEPHRINE; PHOSPHORUS; BOS TAURUS TESTICLE; ONOSMODIUM VIRGINIANUM",
"StrengthNumber": "2; 2; 3; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 9; 12; 12; 16; 30",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2023-11-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230310",
"EndMarketingDatePackage": "20280614",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides male hormonogenic support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0004-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0004-1) ",
"NDC11Code": "83014-0004-01",
"ProductNDC": "83014-0004",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus",
"NonProprietaryName": "Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Pituitarum Posterium (bovine), Thyroidinum (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20230216",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; BOS TAURUS PITUITARY GLAND, POSTERIOR; THYROID, BOVINE; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS",
"StrengthNumber": "2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 8; 6; 9; 9; 9; 12; 12",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2024-05-10",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20230216",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue and resets the hypothalamus.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0005-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0005-1) ",
"NDC11Code": "83014-0005-01",
"ProductNDC": "83014-0005",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus Immune Support",
"NonProprietaryName": "Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Petroselinum Sativum, Capsicum Annuum, Galium Aparine, Hydrastis Canadensis, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Thymus (bovine Thymus Gland), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20230217",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; PETROSELINUM CRISPUM WHOLE; CAPSICUM; GALIUM APARINE WHOLE; GOLDENSEAL; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS THYMUS; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS",
"StrengthNumber": "2; 3; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2024-05-10",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20230217",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides immune support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0006-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0006-1) ",
"NDC11Code": "83014-0006-01",
"ProductNDC": "83014-0006",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus Thyroid",
"NonProprietaryName": "Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin, Rutinic Acid, Iodium, Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Spongia Tosta, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Lapis Albus",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20230822",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPRIC ACID; IODINE; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; SPONGIA OFFICINALIS SKELETON, ROASTED; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CALCIUM HEXAFLUOROSILICATE",
"StrengthNumber": "2; 3; 3; 3; 3; 4; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 15",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2024-05-10",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20230822",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides thyroid support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0007-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0007-1) ",
"NDC11Code": "83014-0007-01",
"ProductNDC": "83014-0007",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus Male Balance",
"NonProprietaryName": "Agnus Castus, Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Selenium Metallicum, Adrenalinum, Phosphorus, Orchitinum (bovine), Caladium Seguinum, Onosmodium Virginianum",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20231030",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "CHASTE TREE FRUIT; FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; SELENIUM; EPINEPHRINE; PHOSPHORUS; BOS TAURUS TESTICLE; DIEFFENBACHIA SEGUINE WHOLE; ONOSMODIUM VIRGINIANUM",
"StrengthNumber": "2; 2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 9; 12; 12; 16; 18; 30",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2024-02-09",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20231030",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides male hormonogenic support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0008-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0008-1) ",
"NDC11Code": "83014-0008-01",
"ProductNDC": "83014-0008",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus Female Balance",
"NonProprietaryName": "Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Caulophyllum Thalictrines, Cimicifuga Racemosa, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Rubus Idaeus, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Hepar Sulphuris Calcareum, Progesterone, Oxytocin",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20240523",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; CAULOPHYLLUM THALICTROIDES ROOT; BLACK COHOSH; GALIUM APARINE WHOLE; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; RUBUS IDAEUS LEAF; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CALCIUM SULFIDE; PROGESTERONE; OXYTOCIN",
"StrengthNumber": "2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 12; 30; 34",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Increased Uterine Smooth Muscle Contraction or Tone [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Oxytocic [EPC], Oxytocin [CS], Plant Proteins [CS], Progesterone [CS], Progesterone [EPC], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2024-05-25",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20240523",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides female hormonogenic balance support. †. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "83014-0100-1",
"PackageDescription": "60 mL in 1 BOTTLE, SPRAY (83014-0100-1) ",
"NDC11Code": "83014-0100-01",
"ProductNDC": "83014-0100",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Weight Loss Support Plus - Glp 1 Booster",
"NonProprietaryName": "Foeniculum Vulgare, Ammonium Bromatum, Berberis Vulgaris, Cinnamomum, Fucus Vesiculosus, Lecithin (derived From Egg), Trigonella Foenum-graecum, Panax Ginseng, Capsicum Annuum, Curcuma Longa, Galium Aparine, Hepar Suis, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Pancreas Suis, Phytolacca Decandra, Small Intestine (suis), Pituitarum Posterium (bovine), Thyroidinum (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus",
"DosageFormName": "SPRAY",
"RouteName": "ORAL",
"StartMarketingDate": "20260129",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Carolinas Weight Loss Institute",
"SubstanceName": "FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; BERBERIS VULGARIS ROOT BARK; CINNAMON; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; FENUGREEK SEED; ASIAN GINSENG; CAPSICUM; TURMERIC; GALIUM APARINE WHOLE; PORK LIVER; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; SUS SCROFA PANCREAS; PHYTOLACCA AMERICANA ROOT; SUS SCROFA INTESTINAL MUCOSA; BOS TAURUS PITUITARY GLAND, POSTERIOR; THYROID, BOVINE; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS",
"StrengthNumber": "2; 3; 3; 3; 3; 3; 3; 4; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 6; 9; 9; 9; 12; 12",
"StrengthUnit": "[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL",
"Pharm_Classes": "Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Dietary Proteins [CS], Food Additives [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-02-02",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20260129",
"SamplePackage": "N",
"IndicationAndUsage": "Appetite suppressant to control empty feeling in stomach otherwise relieved by eating, helps with metabolic tendencies to gain weight, cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides support for the body's production of GLP 1.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
},
{
"NDCCode": "0002-0013-03",
"PackageDescription": "3 mL in 1 VIAL, MULTI-DOSE (0002-0013-03) ",
"NDC11Code": "00002-0013-03",
"ProductNDC": "0002-0013",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SOLUTION",
"StartMarketingDate": "19830627",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2022-03-05",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "04-DEC-09"
},
{
"NDCCode": "0002-0013-10",
"PackageDescription": "10 mL in 1 VIAL, MULTI-DOSE (0002-0013-10) ",
"NDC11Code": "00002-0013-10",
"ProductNDC": "0002-0013",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SOLUTION",
"StartMarketingDate": "19830627",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2022-03-05",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "27-JUN-83"
},
{
"NDCCode": "0002-0095-00",
"PackageDescription": "3 mL in 1 SYRINGE (0002-0095-00) ",
"NDC11Code": "00002-0095-00",
"ProductNDC": "0002-0095",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SOLUTION",
"StartMarketingDate": "20151229",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "500",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2022-03-05",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "29-DEC-15"
},
{
"NDCCode": "0002-0096-00",
"PackageDescription": "20 mL in 1 VIAL, MULTI-DOSE (0002-0096-00) ",
"NDC11Code": "00002-0096-00",
"ProductNDC": "0002-0096",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SOLUTION",
"StartMarketingDate": "19940331",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "500",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2022-03-05",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "06-JAN-97"
},
{
"NDCCode": "0002-0113-03",
"PackageDescription": "3 mL in 1 VIAL, MULTI-DOSE (0002-0113-03) ",
"NDC11Code": "00002-0113-03",
"ProductNDC": "0002-0113",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "19830627",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2022-03-05",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "24-JUN-10"
},
{
"NDCCode": "0002-0113-10",
"PackageDescription": "10 mL in 1 VIAL, MULTI-DOSE (0002-0113-10) ",
"NDC11Code": "00002-0113-10",
"ProductNDC": "0002-0113",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "19830627",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2022-03-05",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "27-JUN-83"
},
{
"NDCCode": "0002-0119-00",
"PackageDescription": "3 mL in 1 SYRINGE (0002-0119-00) ",
"NDC11Code": "00002-0119-00",
"ProductNDC": "0002-0119",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "20131107",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2022-03-05",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "07-NOV-13"
},
{
"NDCCode": "0002-0120-00",
"PackageDescription": "10 mL in 1 VIAL, MULTI-DOSE (0002-0120-00) ",
"NDC11Code": "00002-0120-00",
"ProductNDC": "0002-0120",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Lispro",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "19991222",
"EndMarketingDate": "20240331",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN LISPRO",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Deprecated",
"LastUpdate": "2014-02-04",
"StartMarketingDatePackage": "07-FEB-06",
"EndMarketingDatePackage": "31-MAR-24"
},
{
"NDCCode": "0002-0121-00",
"PackageDescription": "3 mL in 1 SYRINGE (0002-0121-00) ",
"NDC11Code": "00002-0121-00",
"ProductNDC": "0002-0121",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Lispro",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "20070906",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN LISPRO",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2023-09-21",
"ListingRecordCertifiedThrough": "20241231",
"StartMarketingDatePackage": "16-JAN-08"
},
{
"NDCCode": "0002-0124-00",
"PackageDescription": "10 mL in 1 VIAL, MULTI-DOSE (0002-0124-00) ",
"NDC11Code": "00002-0124-00",
"ProductNDC": "0002-0124",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Lispro",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "19991222",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN LISPRO",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2024-07-30",
"ListingRecordCertifiedThrough": "20251231",
"StartMarketingDatePackage": "07-DEC-07"
},
{
"NDCCode": "0002-0124-03",
"PackageDescription": "3 mL in 1 VIAL, MULTI-DOSE (0002-0124-03) ",
"NDC11Code": "00002-0124-03",
"ProductNDC": "0002-0124",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Lispro",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "19991222",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN LISPRO",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2024-07-30",
"ListingRecordCertifiedThrough": "20251231",
"StartMarketingDatePackage": "10-OCT-00"
},
{
"NDCCode": "0002-0137-00",
"PackageDescription": "3 mL in 1 SYRINGE (0002-0137-00) ",
"NDC11Code": "00002-0137-00",
"ProductNDC": "0002-0137",
"ProductTypeName": "DRUG FOR FURTHER PROCESSING",
"NonProprietaryName": "Insulin Lispro",
"DosageFormName": "INJECTION, SUSPENSION",
"StartMarketingDate": "20070906",
"MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN LISPRO",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Status": "Unfinished",
"LastUpdate": "2024-07-30",
"ListingRecordCertifiedThrough": "20251231",
"StartMarketingDatePackage": "16-JAN-08"
},
{
"NDCCode": "0002-0152-01",
"PackageDescription": "1 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-01) / .5 mL in 1 VIAL, SINGLE-DOSE",
"NDC11Code": "00002-0152-01",
"ProductNDC": "0002-0152",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Zepbound",
"NonProprietaryName": "Tirzepatide",
"DosageFormName": "INJECTION, SOLUTION",
"RouteName": "SUBCUTANEOUS",
"StartMarketingDate": "20240328",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA217806",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "TIRZEPATIDE",
"StrengthNumber": "2.5",
"StrengthUnit": "mg/.5mL",
"Pharm_Classes": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-09-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20240328",
"SamplePackage": "N",
"IndicationAndUsage": "ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .",
"Description": "ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming."
},
{
"NDCCode": "0002-0152-04",
"PackageDescription": "4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-04) / .5 mL in 1 VIAL, SINGLE-DOSE",
"NDC11Code": "00002-0152-04",
"ProductNDC": "0002-0152",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Zepbound",
"NonProprietaryName": "Tirzepatide",
"DosageFormName": "INJECTION, SOLUTION",
"RouteName": "SUBCUTANEOUS",
"StartMarketingDate": "20240328",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA217806",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "TIRZEPATIDE",
"StrengthNumber": "2.5",
"StrengthUnit": "mg/.5mL",
"Pharm_Classes": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-09-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20240808",
"SamplePackage": "N",
"IndicationAndUsage": "ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .",
"Description": "ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming."
},
{
"NDCCode": "0002-0152-61",
"PackageDescription": "4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-61) / .5 mL in 1 VIAL, SINGLE-DOSE",
"NDC11Code": "00002-0152-61",
"ProductNDC": "0002-0152",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Zepbound",
"NonProprietaryName": "Tirzepatide",
"DosageFormName": "INJECTION, SOLUTION",
"RouteName": "SUBCUTANEOUS",
"StartMarketingDate": "20240328",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA217806",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "TIRZEPATIDE",
"StrengthNumber": "2.5",
"StrengthUnit": "mg/.5mL",
"Pharm_Classes": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-09-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20250501",
"SamplePackage": "Y",
"IndicationAndUsage": "ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .",
"Description": "ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming."
},
{
"NDCCode": "0002-0213-01",
"PackageDescription": "1 VIAL, MULTI-DOSE in 1 CARTON (0002-0213-01) / 3 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "00002-0213-01",
"ProductNDC": "0002-0213",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Humulin",
"ProprietaryNameSuffix": "R",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "INJECTION, SOLUTION",
"RouteName": "PARENTERAL",
"StartMarketingDate": "19830627",
"EndMarketingDate": "20261215",
"MarketingCategoryName": "BLA",
"ApplicationNumber": "BLA018780",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "100",
"StrengthUnit": "[iU]/mL",
"Pharm_Classes": "Insulin [CS], Insulin [EPC]",
"Status": "Active",
"LastUpdate": "2026-09-08",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230620",
"EndMarketingDatePackage": "20261215",
"SamplePackage": "N",
"IndicationAndUsage": "HUMULIN R is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.",
"Description": "Insulin human is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli and has the empirical formula C257H383N65O77S6 with a molecular weight of 5.808 kDa. HUMULIN R (insulin human) injection is a short-acting human insulin for subcutaneous or intravenous use. HUMULIN R is a sterile, aqueous, clear, and colorless solution. HUMULIN R contains 100 units of insulin human in each milliliter. Each milliliter of HUMULIN R also contains glycerin (16 mg), metacresol (2.5 mg), endogenous zinc (approximately 0.015 mg/100 units,) and Water for Injection. Sodium hydroxide and hydrochloric acid may be added during manufacture to adjust the pH. The pH is 7.0 to 7.8."
},
{
"NDCCode": "0002-0243-01",
"PackageDescription": "1 VIAL, SINGLE-DOSE in 1 CARTON (0002-0243-01) / .5 mL in 1 VIAL, SINGLE-DOSE",
"NDC11Code": "00002-0243-01",
"ProductNDC": "0002-0243",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Zepbound",
"NonProprietaryName": "Tirzepatide",
"DosageFormName": "INJECTION, SOLUTION",
"RouteName": "SUBCUTANEOUS",
"StartMarketingDate": "20240328",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA217806",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "TIRZEPATIDE",
"StrengthNumber": "5",
"StrengthUnit": "mg/.5mL",
"Pharm_Classes": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-09-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20240328",
"SamplePackage": "N",
"IndicationAndUsage": "ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .",
"Description": "ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming."
},
{
"NDCCode": "0002-0243-04",
"PackageDescription": "4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0243-04) / .5 mL in 1 VIAL, SINGLE-DOSE",
"NDC11Code": "00002-0243-04",
"ProductNDC": "0002-0243",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Zepbound",
"NonProprietaryName": "Tirzepatide",
"DosageFormName": "INJECTION, SOLUTION",
"RouteName": "SUBCUTANEOUS",
"StartMarketingDate": "20240328",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA217806",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "TIRZEPATIDE",
"StrengthNumber": "5",
"StrengthUnit": "mg/.5mL",
"Pharm_Classes": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-09-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20240808",
"SamplePackage": "N",
"IndicationAndUsage": "ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .",
"Description": "ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming."
},
{
"NDCCode": "0002-0485-01",
"PackageDescription": "8 BOTTLE in 1 CONTAINER (0002-0485-01) > 2000 g in 1 BOTTLE",
"NDC11Code": "00002-0485-01",
"ProductNDC": "0002-0485",
"ProductTypeName": "BULK INGREDIENT",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "CRYSTAL",
"StartMarketingDate": "20150401",
"MarketingCategoryName": "BULK INGREDIENT",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "1",
"StrengthUnit": "g/g",
"Status": "Deprecated",
"LastUpdate": "2014-02-04",
"ListingRecordCertifiedThrough": "20181231"
},
{
"NDCCode": "0002-0485-04",
"PackageDescription": "4 BOTTLE in 1 CONTAINER (0002-0485-04) > 2000 g in 1 BOTTLE",
"NDC11Code": "00002-0485-04",
"ProductNDC": "0002-0485",
"ProductTypeName": "BULK INGREDIENT",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "CRYSTAL",
"StartMarketingDate": "20150401",
"MarketingCategoryName": "BULK INGREDIENT",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "1",
"StrengthUnit": "g/g",
"Status": "Unfinished",
"LastUpdate": "2022-12-20",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "10-JUL-17"
},
{
"NDCCode": "0002-0485-18",
"PackageDescription": "1 BOTTLE in 1 CONTAINER (0002-0485-18) > 2000 g in 1 BOTTLE",
"NDC11Code": "00002-0485-18",
"ProductNDC": "0002-0485",
"ProductTypeName": "BULK INGREDIENT",
"NonProprietaryName": "Insulin Human",
"DosageFormName": "CRYSTAL",
"StartMarketingDate": "20150401",
"MarketingCategoryName": "BULK INGREDIENT",
"LabelerName": "Eli Lilly and Company",
"SubstanceName": "INSULIN HUMAN",
"StrengthNumber": "1",
"StrengthUnit": "g/g",
"Status": "Unfinished",
"LastUpdate": "2022-12-20",
"ListingRecordCertifiedThrough": "20231231",
"StartMarketingDatePackage": "01-APR-15"
}
]
}
{"NDC":[{"NDCCode":"83014-0002-1","ProprietaryName":"Weight Loss Support Plus Adrenal","NonProprietaryName":"Glycyrrhiza Glabra, Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Aralia Quinquefolia, Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Glandula Suprarenalis (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Adrenocorticotrophin"},{"NDCCode":"83014-0001-1","ProprietaryName":"Weight Loss Support Plus Female Balance","NonProprietaryName":"Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Caulophyllum Thalictroides, Cimicifuga Racemosa, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Rubus Idaeus, Thyroidinum (bovine), Pituitarum Posterium Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Hepar Sulphuris Calcareum, Oxytocin, Progesterone"},{"NDCCode":"83014-0003-1","ProprietaryName":"Weight Loss Support Plus Male Balance","NonProprietaryName":"Agnus Castus, Foeniculum Vulgare, Ammonium Bromatum, Caladium Seguinum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Selenium Metallicum, Adrenalinum, Phosphorus, Orchitinum (bovine), Onosmodium Virginianum"},{"NDCCode":"83014-0004-1","ProprietaryName":"Weight Loss Support Plus","NonProprietaryName":"Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Pituitarum Posterium (bovine), Thyroidinum (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus"},{"NDCCode":"83014-0005-1","ProprietaryName":"Weight Loss Support Plus Immune Support","NonProprietaryName":"Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Petroselinum Sativum, Capsicum Annuum, Galium Aparine, Hydrastis Canadensis, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Thymus (bovine Thymus Gland), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus"},{"NDCCode":"83014-0006-1","ProprietaryName":"Weight Loss Support Plus Thyroid","NonProprietaryName":"Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin, Rutinic Acid, Iodium, Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Spongia Tosta, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Lapis Albus"},{"NDCCode":"83014-0007-1","ProprietaryName":"Weight Loss Support Plus Male Balance","NonProprietaryName":"Agnus Castus, Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Selenium Metallicum, Adrenalinum, Phosphorus, Orchitinum (bovine), Caladium Seguinum, Onosmodium Virginianum"},{"NDCCode":"83014-0008-1","ProprietaryName":"Weight Loss Support Plus Female Balance","NonProprietaryName":"Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Caulophyllum Thalictrines, Cimicifuga Racemosa, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Rubus Idaeus, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Hepar Sulphuris Calcareum, Progesterone, Oxytocin"},{"NDCCode":"83014-0100-1","ProprietaryName":"Weight Loss Support Plus - Glp 1 Booster","NonProprietaryName":"Foeniculum Vulgare, Ammonium Bromatum, Berberis Vulgaris, Cinnamomum, Fucus Vesiculosus, Lecithin (derived From Egg), Trigonella Foenum-graecum, Panax Ginseng, Capsicum Annuum, Curcuma Longa, Galium Aparine, Hepar Suis, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Pancreas Suis, Phytolacca Decandra, Small Intestine (suis), Pituitarum Posterium (bovine), Thyroidinum (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus"},{"NDCCode":"0002-0013-03","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0013-10","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0095-00","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0096-00","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0113-03","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0113-10","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0119-00","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0120-00","NonProprietaryName":"Insulin Lispro"},{"NDCCode":"0002-0121-00","NonProprietaryName":"Insulin Lispro"},{"NDCCode":"0002-0124-00","NonProprietaryName":"Insulin Lispro"},{"NDCCode":"0002-0124-03","NonProprietaryName":"Insulin Lispro"},{"NDCCode":"0002-0137-00","NonProprietaryName":"Insulin Lispro"},{"NDCCode":"0002-0152-01","ProprietaryName":"Zepbound","NonProprietaryName":"Tirzepatide"},{"NDCCode":"0002-0152-04","ProprietaryName":"Zepbound","NonProprietaryName":"Tirzepatide"},{"NDCCode":"0002-0152-61","ProprietaryName":"Zepbound","NonProprietaryName":"Tirzepatide"},{"NDCCode":"0002-0213-01","ProprietaryName":"Humulin","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0243-01","ProprietaryName":"Zepbound","NonProprietaryName":"Tirzepatide"},{"NDCCode":"0002-0243-04","ProprietaryName":"Zepbound","NonProprietaryName":"Tirzepatide"},{"NDCCode":"0002-0485-01","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0485-04","NonProprietaryName":"Insulin Human"},{"NDCCode":"0002-0485-18","NonProprietaryName":"Insulin Human"}]}
<?xml version="1.0" encoding="utf-8"?>
<NDCList>
<NDC>
<NDCCode>83014-0002-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0002-1) </PackageDescription>
<NDC11Code>83014-0002-01</NDC11Code>
<ProductNDC>83014-0002</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus Adrenal</ProprietaryName>
<NonProprietaryName>Glycyrrhiza Glabra, Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Aralia Quinquefolia, Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Glandula Suprarenalis (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Adrenocorticotrophin</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230321</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>GLYCYRRHIZA GLABRA; FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; AMERICAN GINSENG; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS ADRENAL GLAND; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CORTICOTROPIN</SubstanceName>
<StrengthNumber>1; 2; 3; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 15</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Adrenocorticotropic Hormone [CS], Adrenocorticotropic Hormone [EPC], Allergens [CS], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Dietary Proteins [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-03-10</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20230321</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant, to control empty feeling in stomach otherwise relieved by eating, helps with metabolic tendencies to gain weight, cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides adrenal support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0001-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0001-1) </PackageDescription>
<NDC11Code>83014-0001-01</NDC11Code>
<ProductNDC>83014-0001</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus Female Balance</ProprietaryName>
<NonProprietaryName>Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Caulophyllum Thalictroides, Cimicifuga Racemosa, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Rubus Idaeus, Thyroidinum (bovine), Pituitarum Posterium Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Hepar Sulphuris Calcareum, Oxytocin, Progesterone</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230321</StartMarketingDate>
<EndMarketingDate>20290214</EndMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; CAULOPHYLLUM THALICTROIDES ROOT; BLACK COHOSH; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; RUBUS IDAEUS LEAF; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CALCIUM SULFIDE; OXYTOCIN; PROGESTERONE</SubstanceName>
<StrengthNumber>2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 12; 30; 30</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Increased Uterine Smooth Muscle Contraction or Tone [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Oxytocic [EPC], Oxytocin [CS], Plant Proteins [CS], Progesterone [CS], Progesterone [EPC], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2024-05-15</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230321</StartMarketingDatePackage>
<EndMarketingDatePackage>20290214</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides female hormonogenic balance support. †. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0003-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0003-1) </PackageDescription>
<NDC11Code>83014-0003-01</NDC11Code>
<ProductNDC>83014-0003</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus Male Balance</ProprietaryName>
<NonProprietaryName>Agnus Castus, Foeniculum Vulgare, Ammonium Bromatum, Caladium Seguinum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Selenium Metallicum, Adrenalinum, Phosphorus, Orchitinum (bovine), Onosmodium Virginianum</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230310</StartMarketingDate>
<EndMarketingDate>20280614</EndMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>CHASTE TREE FRUIT; FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; DIEFFENBACHIA SEGUINE WHOLE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; SELENIUM; EPINEPHRINE; PHOSPHORUS; BOS TAURUS TESTICLE; ONOSMODIUM VIRGINIANUM</SubstanceName>
<StrengthNumber>2; 2; 3; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 9; 12; 12; 16; 30</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-11-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230310</StartMarketingDatePackage>
<EndMarketingDatePackage>20280614</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides male hormonogenic support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0004-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0004-1) </PackageDescription>
<NDC11Code>83014-0004-01</NDC11Code>
<ProductNDC>83014-0004</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus</ProprietaryName>
<NonProprietaryName>Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Pituitarum Posterium (bovine), Thyroidinum (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230216</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; BOS TAURUS PITUITARY GLAND, POSTERIOR; THYROID, BOVINE; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS</SubstanceName>
<StrengthNumber>2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 8; 6; 9; 9; 9; 12; 12</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2024-05-10</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20230216</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue and resets the hypothalamus.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0005-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0005-1) </PackageDescription>
<NDC11Code>83014-0005-01</NDC11Code>
<ProductNDC>83014-0005</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus Immune Support</ProprietaryName>
<NonProprietaryName>Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Petroselinum Sativum, Capsicum Annuum, Galium Aparine, Hydrastis Canadensis, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum (nspc), Phytolacca Decandra, Thyroidinum (bovine), Thymus (bovine Thymus Gland), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230217</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; PETROSELINUM CRISPUM WHOLE; CAPSICUM; GALIUM APARINE WHOLE; GOLDENSEAL; SUS SCROFA PITUITARY GLAND; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS THYMUS; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS</SubstanceName>
<StrengthNumber>2; 3; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2024-05-10</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20230217</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides immune support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0006-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0006-1) </PackageDescription>
<NDC11Code>83014-0006-01</NDC11Code>
<ProductNDC>83014-0006</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus Thyroid</ProprietaryName>
<NonProprietaryName>Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin, Rutinic Acid, Iodium, Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Spongia Tosta, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Lapis Albus</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230822</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPRIC ACID; IODINE; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; SPONGIA OFFICINALIS SKELETON, ROASTED; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CALCIUM HEXAFLUOROSILICATE</SubstanceName>
<StrengthNumber>2; 3; 3; 3; 3; 4; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 15</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2024-05-10</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20230822</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides thyroid support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0007-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0007-1) </PackageDescription>
<NDC11Code>83014-0007-01</NDC11Code>
<ProductNDC>83014-0007</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus Male Balance</ProprietaryName>
<NonProprietaryName>Agnus Castus, Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Selenium Metallicum, Adrenalinum, Phosphorus, Orchitinum (bovine), Caladium Seguinum, Onosmodium Virginianum</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20231030</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>CHASTE TREE FRUIT; FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; GALIUM APARINE WHOLE; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; SELENIUM; EPINEPHRINE; PHOSPHORUS; BOS TAURUS TESTICLE; DIEFFENBACHIA SEGUINE WHOLE; ONOSMODIUM VIRGINIANUM</SubstanceName>
<StrengthNumber>2; 2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 9; 12; 12; 16; 18; 30</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2024-02-09</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20231030</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides male hormonogenic support.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0008-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0008-1) </PackageDescription>
<NDC11Code>83014-0008-01</NDC11Code>
<ProductNDC>83014-0008</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus Female Balance</ProprietaryName>
<NonProprietaryName>Foeniculum Vulgare, Ammonium Bromatum, Fucus Vesiculosus, Lecithin (derived From Egg), Capsicum Annuum, Caulophyllum Thalictrines, Cimicifuga Racemosa, Galium Aparine, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Phytolacca Decandra, Rubus Idaeus, Thyroidinum (bovine), Pituitarum Posterium (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus, Hepar Sulphuris Calcareum, Progesterone, Oxytocin</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20240523</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; CAPSICUM; CAULOPHYLLUM THALICTROIDES ROOT; BLACK COHOSH; GALIUM APARINE WHOLE; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; PHYTOLACCA AMERICANA ROOT; RUBUS IDAEUS LEAF; THYROID, BOVINE; BOS TAURUS PITUITARY GLAND, POSTERIOR; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS; CALCIUM SULFIDE; PROGESTERONE; OXYTOCIN</SubstanceName>
<StrengthNumber>2; 3; 3; 3; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 9; 9; 9; 12; 12; 12; 30; 34</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Dietary Proteins [CS], Increased Histamine Release [PE], Increased Uterine Smooth Muscle Contraction or Tone [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Oxytocic [EPC], Oxytocin [CS], Plant Proteins [CS], Progesterone [CS], Progesterone [EPC], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2024-05-25</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20240523</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating. Helps with metabolic tendencies to gain weight, helps to suppress cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides female hormonogenic balance support. †. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83014-0100-1</NDCCode>
<PackageDescription>60 mL in 1 BOTTLE, SPRAY (83014-0100-1) </PackageDescription>
<NDC11Code>83014-0100-01</NDC11Code>
<ProductNDC>83014-0100</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Weight Loss Support Plus - Glp 1 Booster</ProprietaryName>
<NonProprietaryName>Foeniculum Vulgare, Ammonium Bromatum, Berberis Vulgaris, Cinnamomum, Fucus Vesiculosus, Lecithin (derived From Egg), Trigonella Foenum-graecum, Panax Ginseng, Capsicum Annuum, Curcuma Longa, Galium Aparine, Hepar Suis, Hypothalamus Suis, Kali Bichromicum, Lac Defloratum, Pancreas Suis, Phytolacca Decandra, Small Intestine (suis), Pituitarum Posterium (bovine), Thyroidinum (bovine), Antimonium Crudum, Argentum Metallicum, Calcarea Carbonica, Adrenalinum, Phosphorus</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20260129</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Carolinas Weight Loss Institute</LabelerName>
<SubstanceName>FOENICULUM VULGARE FRUIT; AMMONIUM BROMIDE; BERBERIS VULGARIS ROOT BARK; CINNAMON; FUCUS VESICULOSUS; EGG PHOSPHOLIPIDS; FENUGREEK SEED; ASIAN GINSENG; CAPSICUM; TURMERIC; GALIUM APARINE WHOLE; PORK LIVER; SUS SCROFA HYPOTHALAMUS; POTASSIUM DICHROMATE; SKIM MILK; SUS SCROFA PANCREAS; PHYTOLACCA AMERICANA ROOT; SUS SCROFA INTESTINAL MUCOSA; BOS TAURUS PITUITARY GLAND, POSTERIOR; THYROID, BOVINE; ANTIMONY TRISULFIDE; SILVER; OYSTER SHELL CALCIUM CARBONATE, CRUDE; EPINEPHRINE; PHOSPHORUS</SubstanceName>
<StrengthNumber>2; 3; 3; 3; 3; 3; 3; 4; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 8; 6; 9; 9; 9; 12; 12</StrengthNumber>
<StrengthUnit>[hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL</StrengthUnit>
<Pharm_Classes>Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Allergens [CS], Allergens [CS], Catecholamine [EPC], Catecholamines [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Dietary Proteins [CS], Food Additives [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Vegetable Proteins [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-02-02</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20260129</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Appetite suppressant to control empty feeling in stomach otherwise relieved by eating, helps with metabolic tendencies to gain weight, cravings. Aids in mobilization of fatty tissue, resets the hypothalamus and provides support for the body's production of GLP 1.†. †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>0002-0013-03</NDCCode>
<PackageDescription>3 mL in 1 VIAL, MULTI-DOSE (0002-0013-03) </PackageDescription>
<NDC11Code>00002-0013-03</NDC11Code>
<ProductNDC>0002-0013</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<StartMarketingDate>19830627</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-03-05</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>04-DEC-09</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0013-10</NDCCode>
<PackageDescription>10 mL in 1 VIAL, MULTI-DOSE (0002-0013-10) </PackageDescription>
<NDC11Code>00002-0013-10</NDC11Code>
<ProductNDC>0002-0013</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<StartMarketingDate>19830627</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-03-05</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>27-JUN-83</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0095-00</NDCCode>
<PackageDescription>3 mL in 1 SYRINGE (0002-0095-00) </PackageDescription>
<NDC11Code>00002-0095-00</NDC11Code>
<ProductNDC>0002-0095</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<StartMarketingDate>20151229</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>500</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-03-05</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>29-DEC-15</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0096-00</NDCCode>
<PackageDescription>20 mL in 1 VIAL, MULTI-DOSE (0002-0096-00) </PackageDescription>
<NDC11Code>00002-0096-00</NDC11Code>
<ProductNDC>0002-0096</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<StartMarketingDate>19940331</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>500</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-03-05</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>06-JAN-97</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0113-03</NDCCode>
<PackageDescription>3 mL in 1 VIAL, MULTI-DOSE (0002-0113-03) </PackageDescription>
<NDC11Code>00002-0113-03</NDC11Code>
<ProductNDC>0002-0113</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>19830627</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-03-05</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>24-JUN-10</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0113-10</NDCCode>
<PackageDescription>10 mL in 1 VIAL, MULTI-DOSE (0002-0113-10) </PackageDescription>
<NDC11Code>00002-0113-10</NDC11Code>
<ProductNDC>0002-0113</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>19830627</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-03-05</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>27-JUN-83</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0119-00</NDCCode>
<PackageDescription>3 mL in 1 SYRINGE (0002-0119-00) </PackageDescription>
<NDC11Code>00002-0119-00</NDC11Code>
<ProductNDC>0002-0119</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>20131107</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-03-05</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>07-NOV-13</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0120-00</NDCCode>
<PackageDescription>10 mL in 1 VIAL, MULTI-DOSE (0002-0120-00) </PackageDescription>
<NDC11Code>00002-0120-00</NDC11Code>
<ProductNDC>0002-0120</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Lispro</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>19991222</StartMarketingDate>
<EndMarketingDate>20240331</EndMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN LISPRO</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Deprecated</Status>
<LastUpdate>2014-02-04</LastUpdate>
<StartMarketingDatePackage>07-FEB-06</StartMarketingDatePackage>
<EndMarketingDatePackage>31-MAR-24</EndMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0121-00</NDCCode>
<PackageDescription>3 mL in 1 SYRINGE (0002-0121-00) </PackageDescription>
<NDC11Code>00002-0121-00</NDC11Code>
<ProductNDC>0002-0121</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Lispro</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>20070906</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN LISPRO</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2023-09-21</LastUpdate>
<ListingRecordCertifiedThrough>20241231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>16-JAN-08</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0124-00</NDCCode>
<PackageDescription>10 mL in 1 VIAL, MULTI-DOSE (0002-0124-00) </PackageDescription>
<NDC11Code>00002-0124-00</NDC11Code>
<ProductNDC>0002-0124</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Lispro</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>19991222</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN LISPRO</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2024-07-30</LastUpdate>
<ListingRecordCertifiedThrough>20251231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>07-DEC-07</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0124-03</NDCCode>
<PackageDescription>3 mL in 1 VIAL, MULTI-DOSE (0002-0124-03) </PackageDescription>
<NDC11Code>00002-0124-03</NDC11Code>
<ProductNDC>0002-0124</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Lispro</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>19991222</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN LISPRO</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2024-07-30</LastUpdate>
<ListingRecordCertifiedThrough>20251231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>10-OCT-00</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0137-00</NDCCode>
<PackageDescription>3 mL in 1 SYRINGE (0002-0137-00) </PackageDescription>
<NDC11Code>00002-0137-00</NDC11Code>
<ProductNDC>0002-0137</ProductNDC>
<ProductTypeName>DRUG FOR FURTHER PROCESSING</ProductTypeName>
<NonProprietaryName>Insulin Lispro</NonProprietaryName>
<DosageFormName>INJECTION, SUSPENSION</DosageFormName>
<StartMarketingDate>20070906</StartMarketingDate>
<MarketingCategoryName>DRUG FOR FURTHER PROCESSING</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN LISPRO</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2024-07-30</LastUpdate>
<ListingRecordCertifiedThrough>20251231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>16-JAN-08</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0152-01</NDCCode>
<PackageDescription>1 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-01) / .5 mL in 1 VIAL, SINGLE-DOSE</PackageDescription>
<NDC11Code>00002-0152-01</NDC11Code>
<ProductNDC>0002-0152</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Zepbound</ProprietaryName>
<NonProprietaryName>Tirzepatide</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<RouteName>SUBCUTANEOUS</RouteName>
<StartMarketingDate>20240328</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA217806</ApplicationNumber>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>TIRZEPATIDE</SubstanceName>
<StrengthNumber>2.5</StrengthNumber>
<StrengthUnit>mg/.5mL</StrengthUnit>
<Pharm_Classes>G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-09-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20240328</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .</IndicationAndUsage>
<Description>ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming.</Description>
</NDC>
<NDC>
<NDCCode>0002-0152-04</NDCCode>
<PackageDescription>4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-04) / .5 mL in 1 VIAL, SINGLE-DOSE</PackageDescription>
<NDC11Code>00002-0152-04</NDC11Code>
<ProductNDC>0002-0152</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Zepbound</ProprietaryName>
<NonProprietaryName>Tirzepatide</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<RouteName>SUBCUTANEOUS</RouteName>
<StartMarketingDate>20240328</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA217806</ApplicationNumber>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>TIRZEPATIDE</SubstanceName>
<StrengthNumber>2.5</StrengthNumber>
<StrengthUnit>mg/.5mL</StrengthUnit>
<Pharm_Classes>G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-09-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20240808</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .</IndicationAndUsage>
<Description>ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming.</Description>
</NDC>
<NDC>
<NDCCode>0002-0152-61</NDCCode>
<PackageDescription>4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-61) / .5 mL in 1 VIAL, SINGLE-DOSE</PackageDescription>
<NDC11Code>00002-0152-61</NDC11Code>
<ProductNDC>0002-0152</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Zepbound</ProprietaryName>
<NonProprietaryName>Tirzepatide</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<RouteName>SUBCUTANEOUS</RouteName>
<StartMarketingDate>20240328</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA217806</ApplicationNumber>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>TIRZEPATIDE</SubstanceName>
<StrengthNumber>2.5</StrengthNumber>
<StrengthUnit>mg/.5mL</StrengthUnit>
<Pharm_Classes>G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-09-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20250501</StartMarketingDatePackage>
<SamplePackage>Y</SamplePackage>
<IndicationAndUsage>ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .</IndicationAndUsage>
<Description>ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming.</Description>
</NDC>
<NDC>
<NDCCode>0002-0213-01</NDCCode>
<PackageDescription>1 VIAL, MULTI-DOSE in 1 CARTON (0002-0213-01) / 3 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>00002-0213-01</NDC11Code>
<ProductNDC>0002-0213</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Humulin</ProprietaryName>
<ProprietaryNameSuffix>R</ProprietaryNameSuffix>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<RouteName>PARENTERAL</RouteName>
<StartMarketingDate>19830627</StartMarketingDate>
<EndMarketingDate>20261215</EndMarketingDate>
<MarketingCategoryName>BLA</MarketingCategoryName>
<ApplicationNumber>BLA018780</ApplicationNumber>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>[iU]/mL</StrengthUnit>
<Pharm_Classes>Insulin [CS], Insulin [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-09-08</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230620</StartMarketingDatePackage>
<EndMarketingDatePackage>20261215</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>HUMULIN R is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.</IndicationAndUsage>
<Description>Insulin human is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli and has the empirical formula C257H383N65O77S6 with a molecular weight of 5.808 kDa. HUMULIN R (insulin human) injection is a short-acting human insulin for subcutaneous or intravenous use. HUMULIN R is a sterile, aqueous, clear, and colorless solution. HUMULIN R contains 100 units of insulin human in each milliliter. Each milliliter of HUMULIN R also contains glycerin (16 mg), metacresol (2.5 mg), endogenous zinc (approximately 0.015 mg/100 units,) and Water for Injection. Sodium hydroxide and hydrochloric acid may be added during manufacture to adjust the pH. The pH is 7.0 to 7.8.</Description>
</NDC>
<NDC>
<NDCCode>0002-0243-01</NDCCode>
<PackageDescription>1 VIAL, SINGLE-DOSE in 1 CARTON (0002-0243-01) / .5 mL in 1 VIAL, SINGLE-DOSE</PackageDescription>
<NDC11Code>00002-0243-01</NDC11Code>
<ProductNDC>0002-0243</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Zepbound</ProprietaryName>
<NonProprietaryName>Tirzepatide</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<RouteName>SUBCUTANEOUS</RouteName>
<StartMarketingDate>20240328</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA217806</ApplicationNumber>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>TIRZEPATIDE</SubstanceName>
<StrengthNumber>5</StrengthNumber>
<StrengthUnit>mg/.5mL</StrengthUnit>
<Pharm_Classes>G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-09-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20240328</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .</IndicationAndUsage>
<Description>ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming.</Description>
</NDC>
<NDC>
<NDCCode>0002-0243-04</NDCCode>
<PackageDescription>4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0243-04) / .5 mL in 1 VIAL, SINGLE-DOSE</PackageDescription>
<NDC11Code>00002-0243-04</NDC11Code>
<ProductNDC>0002-0243</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Zepbound</ProprietaryName>
<NonProprietaryName>Tirzepatide</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<RouteName>SUBCUTANEOUS</RouteName>
<StartMarketingDate>20240328</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA217806</ApplicationNumber>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>TIRZEPATIDE</SubstanceName>
<StrengthNumber>5</StrengthNumber>
<StrengthUnit>mg/.5mL</StrengthUnit>
<Pharm_Classes>G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-09-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20240808</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: : 1 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. , 2 to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. .</IndicationAndUsage>
<Description>ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. Structural formula:. ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5. Each single-patient-use KwikPen contains additional volume to allow for device priming.</Description>
</NDC>
<NDC>
<NDCCode>0002-0485-01</NDCCode>
<PackageDescription>8 BOTTLE in 1 CONTAINER (0002-0485-01) > 2000 g in 1 BOTTLE</PackageDescription>
<NDC11Code>00002-0485-01</NDC11Code>
<ProductNDC>0002-0485</ProductNDC>
<ProductTypeName>BULK INGREDIENT</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>CRYSTAL</DosageFormName>
<StartMarketingDate>20150401</StartMarketingDate>
<MarketingCategoryName>BULK INGREDIENT</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>1</StrengthNumber>
<StrengthUnit>g/g</StrengthUnit>
<Status>Deprecated</Status>
<LastUpdate>2014-02-04</LastUpdate>
<ListingRecordCertifiedThrough>20181231</ListingRecordCertifiedThrough>
</NDC>
<NDC>
<NDCCode>0002-0485-04</NDCCode>
<PackageDescription>4 BOTTLE in 1 CONTAINER (0002-0485-04) > 2000 g in 1 BOTTLE</PackageDescription>
<NDC11Code>00002-0485-04</NDC11Code>
<ProductNDC>0002-0485</ProductNDC>
<ProductTypeName>BULK INGREDIENT</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>CRYSTAL</DosageFormName>
<StartMarketingDate>20150401</StartMarketingDate>
<MarketingCategoryName>BULK INGREDIENT</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>1</StrengthNumber>
<StrengthUnit>g/g</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-12-20</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>10-JUL-17</StartMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>0002-0485-18</NDCCode>
<PackageDescription>1 BOTTLE in 1 CONTAINER (0002-0485-18) > 2000 g in 1 BOTTLE</PackageDescription>
<NDC11Code>00002-0485-18</NDC11Code>
<ProductNDC>0002-0485</ProductNDC>
<ProductTypeName>BULK INGREDIENT</ProductTypeName>
<NonProprietaryName>Insulin Human</NonProprietaryName>
<DosageFormName>CRYSTAL</DosageFormName>
<StartMarketingDate>20150401</StartMarketingDate>
<MarketingCategoryName>BULK INGREDIENT</MarketingCategoryName>
<LabelerName>Eli Lilly and Company</LabelerName>
<SubstanceName>INSULIN HUMAN</SubstanceName>
<StrengthNumber>1</StrengthNumber>
<StrengthUnit>g/g</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-12-20</LastUpdate>
<ListingRecordCertifiedThrough>20231231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>01-APR-15</StartMarketingDatePackage>
</NDC>
</NDCList>